Heron Therapeutics, a leading pharmaceutical company, has announced a new distributor partnership with CrossLink Life Sciences. This five-year partnership aims to bolster the sales network for Heron’s innovative product, Zynrelef bupivacaine and meloxicam extended-release solution.
Increased Market Presence
The partnership will be rolled out in several phases, starting with a regional launch and later expanding to a national scale. This strategic approach ensures an effective market penetration for Zynrelef and allows for optimized promotional efforts.
Strengthened Sales Force
To support this expansion, Heron plans to add around 650 representatives to their sales network within the next year. CrossLink will be leading the efforts in the United States, focusing on promoting Zynrelef for orthopedic indications.
Under the terms of the agreement, CrossLink will receive compensation based on a fixed-fee per vial basis. This compensation structure takes into account the growth of Zynrelef sales over a predetermined baseline period.
Zynrelef is a groundbreaking dual-acting local anesthetic that combines bupivacaine, a potent anesthetic, with a low dose of meloxicam, a nonsteroidal anti-inflammatory drug. This unique formulation allows for superior pain relief and enhanced patient outcomes.
Through this strategic partnership, Heron Therapeutics aims to expand the reach of Zynrelef and provide patients struggling with orthopedic conditions with a much-needed solution.